http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-112688-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6835 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6841 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
| filingDate | 2018-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e961079999cd5402519edb7be4b64dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_507fde091fc629208fdd18eec75a7f4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcf32243d894cc9f247dc052b45a7ce7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a942a355fc8848dd69a8e018bf58b257 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89b8fea71f9f474816dd8b5108ddd930 |
| publicationDate | 2019-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-112688-A1 |
| titleOfInvention | TOLL 7-TYPE RECEPTOR AGONISTS (TLR7) HAVING A PYRIDINE OR PIRAZINE PORTION, CONJUGATES OF THESE, AND METHODS AND USES OF THEM |
| abstract | Claim 1: A compound characterized in that it has a structure according to formula (1), wherein Ar is a compound selected from the group of formulas (2); R¹ is (C₁₋₅ alkyl) O, (C₁₋₂ alkyl) O (CH₂) ₂₋₃O, (C₁₋₅ alkyl) C (= O) O, (C₁₋₅ alkyl) NH, (C₁₋₂ alkyl ) O (CH₂) ₂₋₃NH or (C₁₋₅ alkyl) C (= O) NH; R² is, independently of each occurrence, H, C₁₋₃ alkyl, halo, O (C₁₋₃ alkyl), CN or NO₂; and R³ and R⁴ are independently H; C₁₋₆ alkyl; (CH₂) ₂₋₄OH; (CH₂) ₂₋₄O (C₁₋₃ alkyl); (CH₂) ₂₋₄NH₂; (CH₂) ₂₋₄NH (C₁₋₃ alkyl); (CH₂) ₂₋₄N (C₁₋₃ alkyl); (CH₂) ₁₋₃ (aryl); (CH₂) ₁₋₃ (heteroaryl); (CH₂) ₂₋₄ (OCH₂CH₂) ₂₋₈ (CH₂) ₂₋₄NHBoc; a moiety of formula (3), where a CH₂ group on the cycloaliphatic ring can be replaced by O, S, NH or N (C₁₋₃ alkyl), and the cycloaliphatic ring can be substituted with C₁₋₃ alkyl, OH, O (C₁₋₃ alkyl), halo, (CH₂) ₀₋₃NH₂ or (CH₂) ₀₋₃NH (C₁₋₃ alkyl); or R³ and R⁴, in combination with the nitrogen to which they are attached, form a cyclic amine of the structure of formula (4), where a CH₂ group on the cycloaliphatic ring that is separated from the amine nitrogen in at least two groups CH₂ can be replaced by O, S, NH or N (C₁₋₃ alkyl) and the cyclic amine can be substituted with C₁₋₃ alkyl, OH, O (C₁₋₃ alkyl), halo, (CH₂) ₀₋₃NH₂ or (CH₂) ₀₋₃NH (C₁₋₃ alkyl). |
| priorityDate | 2017-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.